Analyzing the genetic factors of hidradenitis suppurativa
Official title: Whole genome sequencing analysis of hidradenitis suppurativa
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-10981631 · Data updated 2026-11-12
This study is looking at how genetics might play a role in hidradenitis suppurativa, a painful skin condition, by comparing samples from African American, Hispanic/Latino, and White patients to understand why the disease affects different groups in different ways, and your participation could help us learn more about it!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | September 18, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $718,693 |
| NIH project number | 1R01AR083553-01A1 |
| Project ID | NIH-10981631 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with hidradenitis suppurativa, particularly those from African American and Hispanic/Latino backgrounds.
✕Less likely to help
Patients who do not have hidradenitis suppurativa or those outside the specified racial groups may not benefit from this research.
What this research studies
This research investigates hidradenitis suppurativa (HS), a chronic skin condition that causes painful nodules and abscesses. By utilizing whole genome sequencing, the study aims to identify genetic variations that contribute to the risk of HS, particularly focusing on differences among African American, Hispanic/Latino, and White patients. The research will explore how these genetic factors may explain the disparities in disease prevalence and severity across different racial groups. Patients may be asked to provide genetic samples and health information to help uncover these associations.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients suffering from hidradenitis suppurativa.
How similar studies have gone: Previous research has shown promising results in understanding genetic contributions to other chronic conditions, suggesting potential for success in this novel approach.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Mi, Qing-Sheng — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Mi, Qing-Sheng
Related research
Other NIH-funded projects on the same topics.
-
Anti-CD38 immunotherapy for severe hidradenitis suppurativa
A new treatment using anti-CD38 therapy is being tested for people with severe hidradenitis suppurativa who have not responded to prior therapies.
-
Botulinum toxin blocks nerve signals to immune cells to treat hidradenitis suppurativa
This NIH grant tests a new approach to hidradenitis suppurativa by using botulinum toxin to interrupt nerve signals that may drive skin inflammation in patients.
-
Precision therapies for hidradenitis suppurativa using AI
A doctor-researcher team at UC San Francisco is using advanced computer methods to find personalized drug options to treat hidradenitis suppurativa.
-
Injectable Hydrogel for HS: a localized therapy to ease painful skin disease
A new baricitinib hydrogel is being developed to deliver pain relief and reduce inflammation directly in hidradenitis suppurativa (HS) lesions, potentially lowering systemic side effects.
-
Whole-genome sequencing to understand hidradenitis suppurativa in diverse groups
Researchers will study the genetic factors that contribute to hidradenitis suppurativa, especially in African American, Hispanic/Latino, and White patients, to better understand why some people are more affected.
-
Understanding the Genes Behind Hidradenitis Suppurativa in teens and young adults
A study to find genetic factors that contribute to hidradenitis suppurativa (HS), a painful skin condition that often starts in adolescence and affects many Black individuals.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.